Contents

Preface *XIII*
A Personal Foreword *XV*

1 Origin and Historical Perspective on Reactive Metabolites *1*
Abbreviations *1*
1.1 Mutagenesis and Carcinogenesis *1*
1.2 Detection of Reactive Metabolites *3*
1.3 Induction and Inhibition: Early Probes for Reactive Metabolites and Hepatotoxicants *4*
1.4 Covalent Binding and Oxidative Stress: Possible Mechanisms of Reactive Metabolite Cytotoxicity *5*
1.5 Activation and Deactivation: Intoxication and Detoxification *6*
1.6 Genetic Influences on Reactive Metabolite Formation *6*
1.7 Halothane: the Role of Reactive Metabolites in Immune-Mediated Toxicity *7*
1.8 Formation of Reactive Metabolites, Amount Formed, and Removal of Liability *8*
1.9 Antibodies: Possible Clues but Inconclusive *8*
1.10 Parent Drug and Not Reactive Metabolites, Complications in Immune-Mediated Toxicity *9*
1.11 Reversible Pharmacology Should not be Ignored as a Primary Cause of Side Effects *10*
1.12 Conclusions: Key Points in the Introduction *10*
References *11*

2 Role of Reactive Metabolites in Genotoxicity *13*
Abbreviations *13*
2.1 Introduction *13*
2.2 Carcinogenicity of Aromatic and Heteroaromatic Amines *13*
2.3 Carcinogenicity of Nitrosamines *17*
2.4 Carcinogenicity of Quinones and Related Compounds *19*
2.5 Carcinogenicity of Furan *23*
2.6 Carcinogenicity of Vinyl Halides *26*

2.7 Carcinogenicity of Ethyl Carbamate *26*
2.8 Carcinogenicity of Dihaloalkanes *28*
2.9 Assays to Detect Metabolism-Dependent Genotoxicity in Drug Discovery *28*
2.10 Case Studies in Eliminating Metabolism-Based Mutagenicity in Drug Discovery Programs *29*
References *36*

3 Bioactivation and Inactivation of Cytochrome P450 and Other Drug-Metabolizing Enzymes *43*
Abbreviations *43*
3.1 Introduction *43*
3.2 Pharmacokinetic and Enzyme Kinetic Principles Underlying Mechanism-Based Inactivation and Drug–Drug Interactions *44*
3.2.1 Enzyme Kinetic Principles of Mechanism-Based Inactivation *44*
3.2.2 Pharmacokinetic Principles Underlying DDIs Caused by Mechanism-Based Inactivation *46*
3.3 Mechanisms of Inactivation of Cytochrome P450 Enzymes *47*
3.3.1 Quasi-Irreversible Inactivation *47*
3.3.2 Heme Adducts *48*
3.3.3 Protein Adducts *49*
3.4 Examples of Drugs and Other Compounds that are Mechanism-Based Inactivators of Cytochrome P450 Enzymes *49*
3.4.1 Amines *49*
3.4.2 Methylenedioxyphenyl Compounds *51*
3.4.3 Quinones, Quinone Imines, and Quinone Methides *52*
3.4.4 Thiophenes *53*
3.4.5 Furans *55*
3.4.6 Alkynes *56*
3.4.7 2-Alkylimidazoles *57*
3.4.8 Other Noteworthy Cytochrome P450 Inactivators *58*
3.5 Mechanism-Based Inactivation of Other Drug-Metabolizing Enzymes *60*
3.5.1 Aldehyde Oxidase *60*
3.5.2 Monoamine Oxidases *61*
3.6 Concluding Remarks *64*
References *65*

4 Role of Reactive Metabolites in Drug-Induced Toxicity – The Tale of Acetaminophen, Halothane, Hydralazine, and Tienilic Acid *71*
Abbreviations *71*
4.1 Introduction *71*
4.2 Acetaminophen *71*
4.2.1 Metabolism of Acetaminophen *72*
4.2.2 Metabolic Activation of Acetaminophen *73*

4.3 Halothane *75*
4.3.1 Metabolism of Halothane *76*
4.3.2 Hepatotoxicity following Halothane Administration *78*
4.4 Hydralazine *79*
4.5 Tienilic Acid *82*
References *84*

5 Pathways of Reactive Metabolite Formation with Toxicophores/-Structural Alerts *93*
Abbreviations *93*
5.1 Introduction *93*
5.2 Intrinsically Reactive Toxicophores *93*
5.2.1 Electrophilic Functional Groups *94*
5.2.2 Metal Complexing Functional Groups *96*
5.3 Toxicophores that Require Bioactivation to Reactive Metabolites *98*
5.3.1 Aromatic Amines (Anilines) *98*
5.3.2 *ortho*- and *para*-Aminophenols *101*
5.3.3 Nitroarenes *103*
5.3.4 Hydrazines *105*
5.3.5 Five-Membered Heteroaromatic Rings *107*
5.3.5.1 Furans *107*
5.3.5.2 Thiophenes *109*
5.3.5.3 Thiazoles and 2-Aminothiazoles *109*
5.3.5.4 3-Alkyl Pyrrole and 3-Alkylindole Derivatives *112*
5.3.5.5 1,3-Benzdioxole (Methylenedioxyphenyl) Motif *115*
5.3.6 Terminal Alkenes and Alkynes *117*
5.4 Concluding Remarks *121*
References *121*

6 Intrinsically Electrophilic Compounds as a Liability in Drug Discovery *131*
Abbreviations *131*
6.1 Introduction *131*
6.2 Intrinsic Electrophilicity of β-Lactam Antibiotics as a Causative Factor in Toxicity *131*
6.3 Intrinsically Electrophilic Compounds in Drug Discovery *133*
6.3.1 Linking Innate Electrophilicity with Drug Toxicity *135*
6.4 Serendipitous Identification of Intrinsically Electrophilic Compounds in Drug Discovery *136*
References *141*

7 Role of Reactive Metabolites in Pharmacological Action *145*
Abbreviations *145*
7.1 Introduction *145*

7.2 Drugs Activated Nonenzymatically and by Oxidative Metabolism *145*
7.2.1 Proton Pump Inhibitors *145*
7.2.2 Nitrosoureas *147*
7.2.3 Imidazotriazenes *148*
7.2.4 Thienotetrahydropyridines *150*
7.2.5 Oxazaphosphorines *152*
7.2.6 *N,N,N′,N′,N″,N″*-Hexamethylmelamine *153*
7.3 Bioreductive Activation of Drugs *153*
7.3.1 Bioreduction to Radical Intermediates *157*
7.3.1.1 Tirapazamine *157*
7.3.1.2 Anthracyclines *157*
7.3.1.3 Enediynes *158*
7.3.1.4 Artemisinin Derivatives *166*
7.3.2 Bioreductive Activation to Electrophilic Intermediates *168*
7.3.2.1 Mitomycins *168*
7.3.2.2 Aziridinylbenzoquinones *170*
7.3.2.3 Bioreductive Activation of Anthracyclines to Alkylating Species *173*
7.3.2.4 Bioreductive Activation of Nitroaromatic Compounds *174*
7.4 Concluding Remarks *175*
References *176*

8 Retrospective Analysis of Structure–Toxicity Relationships of Drugs *185*
Abbreviations *185*
8.1 Introduction *185*
8.2 Irreversible Secondary Pharmacology *189*
8.2.1 Common Structural Features: Carboxylic Acids *189*
8.3 Primary Pharmacology and Irreversible Secondary Pharmacology *191*
8.4 Primary or Secondary Pharmacology and Reactive Metabolites: the Possibility for False Structure–Toxicity Relationships *192*
8.5 Multifactorial Mechanisms as Causes of Toxicity *196*
8.6 Clear Correlation between Protein Target and Reactive Metabolites *197*
8.7 Conclusion – Validation of Reactive Metabolites as Causes of Toxicity *198*
References *200*

9 Bioactivation and Natural Products *203*
Abbreviations *203*
9.1 Introduction *203*
9.2 Well-Known Examples of Bioactivation of Compounds Present in Herbal Remedies *205*
9.2.1 Germander and Teucrin A *205*
9.2.2 Pennyroyal Oil and Menthofuran *207*

9.2.3 *Aristolochia* and Aristolochic Acid *208*
9.2.4 Comfrey, Coltsfoot, and Pyrrolizidine Alkaloids *210*
9.3 Well-Known Examples of Bioactivation of Compounds Present in Foods *212*
9.3.1 Cycasin *212*
9.3.2 Aflatoxin *214*
9.3.3 3-Methylindole *216*
9.3.4 Polycyclic Azaheterocyclic Compounds in Cooked Meats *216*
9.3.5 Nitrosamines *219*
9.4 Summary *220*
References *220*

10 Experimental Approaches to Reactive Metabolite Detection *225*
Abbreviations *225*
10.1 Introduction *225*
10.2 Identification of Structural Alerts and Avoiding them in Drug Design *225*
10.3 Assays for the Detection of Reactive Metabolites *227*
10.3.1 Qualitative Electrophile Trapping Assays *227*
10.3.2 Quantitative Electrophile Trapping Assays *230*
10.3.3 Covalent Binding Assays *231*
10.3.4 Detecting and Characterizing Bioactivation by Enzymes Other than Cytochrome P450 *233*
10.4 Other Studies that can Show the Existence of Reactive Metabolites *234*
10.4.1 Metabolite Identification Studies *234*
10.4.2 Radiolabeled Metabolism and Excretion *In Vivo* *235*
10.4.3 Whole-Body Autoradiography and Tissue Binding *236*
10.4.4 Inactivation of Cytochrome P450 Enzymes *237*
10.5 Conclusion *237*
References *238*

11 Case Studies on Eliminating/Reducing Reactive Metabolite Formation in Drug Discovery *241*
Abbreviations *241*
11.1 Medicinal Chemistry Tactics to Eliminate Reactive Metabolite Formation *241*
11.2 Eliminating Reactive Metabolite Formation on Heterocyclic Ring Systems *242*
11.2.1 Mechanism(s) of Thiazole Ring Bioactivation and Rational Chemistry Approaches to Abolish Reactive Metabolite Formation *242*
11.2.2 Mechanism(s) of Isothiazole Ring Bioactivation and Rational Chemistry Approaches to Abolish Reactive Metabolite Formation *249*
11.3 Medicinal Chemistry Strategies to Mitigate Bioactivation of Electron-Rich Aromatic Rings *251*

11.4 Medicinal Chemistry Strategies to Mitigate Bioactivation on a Piperazine Ring System *256*
11.5 4-Fluorofelbamate as a Potentially Safer Alternative to Felbamate *258*
11.6 Concluding Remarks *263*
References *263*

12 Structural Alert and Reactive Metabolite Analysis for the Top 200 Drugs in the US Market by Prescription *269*
Abbreviations *269*
12.1 Introduction *269*
12.2 Structural Alert and Reactive Metabolite Analyses for the Top 20 Most Prescribed Drugs in the United States for the Year 2009 *270*
12.2.1 Daily Dose Trends *270*
12.2.2 Presence of Structural Alerts *270*
12.2.3 Evidence for Metabolic Activation to Reactive Metabolites *275*
12.3 Insights Into the Excellent Safety Records for Reactive Metabolite–Positive Blockbuster Drugs *280*
12.4 Structural Alert and Reactive Metabolite Analyses for the Remaining 180 Most Prescribed Drugs *282*
12.4.1 Structural Alert and/or Reactive Metabolite "False Positives" *289*
12.5 Structure Toxicity Trends *302*
12.5.1 Meloxicam versus Sudoxicam *304*
12.5.2 Zolpidem versus Alpidem *304*
12.5.3 Quetiapine versus Olanzapine versus Clozapine *304*
References *306*

13 Mitigating Toxicity Risks with Affinity Labeling Drug Candidates *313*
Abbreviations *313*
13.1 Introduction *313*
13.2 Designing Covalent Inhibitors *313*
13.2.1 Selection of Warheads *316*
13.2.2 Reversible Covalent Modification *322*
13.3 Optimization of Chemical Reactivity of the Warhead Moiety *326*
13.3.1 Experimental Approaches *326*
13.3.2 *In Silico* Approaches *328*
13.3.3 Additional Derisking Factors *329*
13.4 Concluding Remarks *329*
References *330*

14 Dealing with Reactive Metabolite–Positive Compounds in Drug Discovery *335*
Abbreviations *335*
14.1 Introduction *335*
14.2 Avoiding the Use of Structural Alerts in Drug Design *336*
14.3 Structural Alert and Reactive Metabolite Formation *338*

14.4 Should Reactive Metabolite–Positive Compounds be Nominated as Drug Candidates? *340*
14.4.1 Impact of Competing, Detoxification Pathways *341*
14.4.2 The Impact of Dose Size *342*
14.4.3 Consideration of the Medical Need/Urgency *345*
14.4.4 Consideration of the Duration of Treatment *345*
14.4.5 Consideration of Novel Pharmacological Targets *346*
14.5 The Multifactorial Nature of IADRs *348*
14.6 Concluding Remarks *350*
References *351*

15 Managing IADRs – a Risk–Benefit Analysis *357*
Abbreviations *357*
15.1 Risk–Benefit Analysis *357*
15.2 How Common is Clinical Drug Toxicity? *359*
15.3 Rules and Laws of Drug Toxicity *363*
15.4 Difficulties in Defining Cause and Black Box Warnings *365*
15.5 Labeling Changes, Contraindications, and Warnings: the Effectiveness of Side Effect Monitoring *367*
15.6 Allele Association with Hypersensitivity Induced by Abacavir: Toward a Biomarker for Toxicity *369*
15.7 More Questions than Answers: Benefit Risk for ADRs *373*
References *374*

Index *377*